The thesis
Channel-pullback is a disciplined mean-reversion-within-trend strategy: it buys dips toward the lower regression channel or volume support only in confirmed uptrends, then exits into the upper channel or resistance. It trades a 24-name large-cap universe spanning tech, financials, healthcare, staples and energy (AAPL, MSFT, NVDA, JPM, V, JNJ, XOM and others). The logic is intuitive and well-grounded — buy strength on weakness — but intuitive is not the same as robust.
Recent activity
The strategy is live and trading on schedule. Over the Nov 6–13 runs it executed 1–2 orders per day with zero rejections, cycling in and out of AAPL repeatedly (buying near $348–$355, selling near $351–$357) and rotating through MSFT ($535–$547) and a chunky 69-share PFE buy at $28.94. That churn is consistent with the backtest's eye-watering 2,311% turnover — this is a high-frequency rotator, not a buy-and-hold book.
The sobering detail is the balance. The live total sits at $9,875 as of Nov 13, having drifted between roughly $9,855 and $9,906 all week — modestly below the ~$10,000 base the backtest started from. Early live results are not yet justifying the thesis.
Backtest and validation
Headline numbers look acceptable at a glance: +7.62% total return, 4.19% CAGR, a 14.83% max drawdown and 137 trades over 451 days. But the Sharpe is a thin 0.40, and the win rate is just 39.4% — the strategy makes money only because its winners outsize its losers, an asymmetry that is notoriously fragile.
Validation tells the real story, and it did not pass. Across four walk-forward folds, three were positive but one — the Jan–Jul 2025 window — lost 11.42% with a Sharpe of −1.70 and a 16% drawdown. Fold 3 then returned a spectacular +20.68% (Sharpe 3.86). That dispersion, from deeply negative to exceptional, is the signature of a strategy whose edge is regime-dependent rather than persistent.
The statistical gates confirm the caution. The Probabilistic Sharpe Ratio (0.70) is middling, but the Deflated Sharpe Ratio is only 0.196 after accounting for 7 trials — well short of confidence that the result isn't selection luck. Out-of-sample return (3.63%) and Sharpe (0.74) are positive but roughly half the in-sample figures, the usual decay.
Verdict
Strengths: a coherent, risk-aware entry logic, clean execution, zero FX drag, and genuine upside in trending markets. Risks: a sub-40% win rate, heavy turnover, one brutal losing fold, and a failing deflated-Sharpe gate that says the backtest edge may not survive contact with new data — a warning the live book is currently echoing.
Channel-pullback stays live as a monitored experiment, not a conviction allocation. The next few months of out-of-sample trading, especially through any downtrend, will decide whether the thesis has a durable edge or merely a lucky fold.